Ametus Group will commercialize a novel treatment for diabetic foot ulcers developed by SANUWAVE Health Inc., moving the dermaPACE System into more markets faster than expected.

Ametus Group has 50 wound care sales members who will commercialize and promote the product — which uses a form of shock wave therapy — across their territories. The emphasis on dermaPACE has already started in Minnesota, Wisconsin and Illinois. Western states are expected to get increased exposure in 2020.

“We are very motivated by the positive clinical impact dermaPACE will have on thousands of diabetic patients with chronic foot ulcers,” Ametus Group Co-founders and Managing Partners Randy Seeliger and Mark Will said in an announcement. “Our partnership with SANUWAVE and the dermaPACE® System are highly accretive with other innovative advanced wound care product offerings Ametus Group currently sells.”